• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

CRISPR Therapeutics AG (CRSP)

Common Shares
Sell: $37.57|Buy: $37.90|Change: 0.94 (-2.43%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Address

Aeschenvorstadt 36
Basel
CHE
4051

Telephone

+1 339 9702843

Website

https://www.crisprtx.com

Sector 

Healthcare

Forecast key dates

NameKey Date
CRISPR Therapeutics AG Fourth Quarter Earnings Results for 20252026-02-11T00:00:00
CRISPR Therapeutics AG Annual Report for 20252026-02-11T00:00:00
CRISPR Therapeutics AG Third Quarter Earnings Results for 20252025-11-05T00:00:00
CRISPR Therapeutics AG Second Quarter Earnings Results for 20252025-08-05T00:00:00
CRISPR Therapeutics AG Annual General Meeting for 20252025-05-30T02:00:00
CRISPR Therapeutics AG First Quarter Earnings Results for 20252025-05-08T00:00:00

Previous key dates

NameKey Date
CRISPR Therapeutics AG Annual General Meeting for 20252025-05-30T02:00:00
CRISPR Therapeutics AG First Quarter Earnings Results for 20252025-05-08T00:00:00
24th Annual Needham Virtual Healthcare Conference2025-04-08T12:45:00
TD Cowen 45th Annual Health Care Conference2025-03-03T10:30:00
CRISPR Therapeutics AG Fourth Quarter Earnings Results for 20242025-02-11T00:00:00
CRISPR Therapeutics AG Annual Report for 20242025-02-11T00:00:00
Guggenheim SMID Cap Biotech Conference2025-02-05T14:00:00
43rd Annual J.P. Morgan Healthcare Conference2025-01-14T14:15:00
Jefferies London Healthcare Conference2024-11-20T16:00:00
Guggenheim Inaugural Healthcare Innovation Conference2024-11-12T14:00:00
CRISPR Therapeutics AG Third Quarter Earnings Results for 20242024-11-05T00:00:00
CRISPR Therapeutics AG Second Quarter Earnings Results for 20242024-08-05T00:00:00
Goldman Sach's 45th Annual Global Healthcare Conference2024-06-11T09:20:00
Jefferies Healthcare Conference2024-06-05T10:00:00
CRISPR Therapeutics AG Annual General Meeting for 20242024-05-30T02:00:00
CRISPR Therapeutics AG First Quarter Earnings Results for 20242024-05-08T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.